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Small interfering RNA (siRNA)-mediated gene therapy is a promising strategy to
temporarily inhibit the expression of proteins implicated in carcinogenesis or
chemotherapy resistance. Although intra-tumoral administration can be envisaged,
studies currently focus on formulating nanomedicines for intravenous injection to
target tumor sites as well as metastases. The development of synthetic
nanoparticles and liposomes has advanced greatly during the last decade. The
objective of this work consists in formulating and optimizing the encapsulation of
siRNA into lipid nanocapsules (LNCs) for efficient gene therapy to target melanoma
cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA
amount and lipid/siRNA charge ratio were assayed to improve the stability and the
encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC
morphology revealed specific organization of the siRNA DOTAP/DOPE lipoplexes as
well as specific lipid microstructures that can be eliminated by purification. No
cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was
observed at concentrations of up to 500 ng/mL siRNA. In vitro siRNA transfection
experiments, compared to Oligofectamine™, demonstrated interesting targeted
gene silencing effects. Finally, complement activation assays confirmed the
feasibility of the PEGylation of siRNA LNCs as part of a passive targeting strategy
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